Lumiracoxib in the management of osteoarthritis and acute pain

Bibliography

• DIEPPE PA, LOHMANDER LS: Pathogenesis and management of pain in osteoarthritis. Lancet (2005) 365(March 12):965-973.
   PubMed Web of Science ®Google Scholar
• JORDAN KM, ARDEN NK, DOHERTY M et al.: EULAR recommendations 2003 : an evidence based approach to the management of knee osteoarthritis : report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann. Rheum. Dis. (2003) 62(12):1145-1155.
   PubMed Web of Science ®Google Scholar
• ZHANG W, DOHERTY M, ARDEN N et al.: EULAR evidence based recommendations for the management of hip osteoarthritis : report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. (2005) 64(5):669-681.
   PubMed Web of Science ®Google Scholar
• AMERICAN COLLEGE OF RHEUMATOLOGYSUBCOMMITTE ON OSTEOARTHRITIS GUIDELINES: Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 Update. Arthritis Rheum. (2000) 43(9):1905-1915.
   PubMedGoogle Scholar
• BANNWARTH B: Acetaminophen or NSAIDs for the treatment of osteoarthritis. Best Pract. Res. Clin. Rheumatol. (2006) 20(1):117-129.
   PubMed Web of Science ®Google Scholar
• ZELENAKAS K, FRICKE Jr JR, JAYAWARDENE S, KELLSTEIN D: Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental pain. Int. J. Clin. Pract. (2004) 58(3):251-256.
   PubMedGoogle Scholar
• BUVANENDRAN A, KROIN JS, TUMAN KJ et al.: Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial. JAMA (2003) 290(18):2411-2418.
   PubMed Web of Science ®Google Scholar
• HYLLESTED M, JONES S, PEDERSEN JL, KEHLET H: Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management : a qualitative review. Br. J. Anaesth. (2002) 88(2):199-214.
   PubMed Web of Science ®Google Scholar
• LEFEBVRE G, PINSONNEAULT O, ANTAO V et al.: Primary dysmenorrhea consensus guideline. J. Obstet. Gynaecol. Can. (2005) 27(12):1117-1146.
   PubMedGoogle Scholar
• SEAGER JM, HAWKEY J: Indigestion and non-steroidal anti-inflammatory drugs. BMJ (2001) 328:1236-1239.
   Google Scholar
• PETERSON WL, CRYER B: COX-1 sparing NSAIDs. Is the enthusiasm justified ? JAMA (1999) 282(20):1961-1963.
   PubMed Web of Science ®Google Scholar
• BANNWARTH B: Do selective cyclo-oxygenase-2 inhibitors have a future ? Drug Saf. (2005) 28(3):183-189.
   PubMed Web of Science ®Google Scholar
• KEARNEY PM, BAIGENT C, GODWIN J, HALLS H, EMBERSON JR, PATRONO C: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis ? Meta-analysis of randomised trials. BMJ (2006) 322(June3):1302-1305.
   Google Scholar
• LOHMANDER LS, McKEITH D, SVENSSON O et al.: A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann. Rheum. Dis. (2005) 64(3):449-456.
   PubMed Web of Science ®Google Scholar
• ALVARO-GRACIA JM: Licofelone. Clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology (2004) 43(Suppl.1):i21-i25.
   PubMed Web of Science ®Google Scholar
• BANNWARTH B, BERENBAUM F: Clinical pharmacology of lumiracoxib, a second generation cyclo-oxygenase 2 selective inhibitor. Expert Opin. Invest. Drugs (2005) 14(4):521-533.
   PubMed Web of Science ®Google Scholar
• CAPONE ML, TACCONNELLI S, SCIULLI MG, PATRIGNANI P: Clinical pharmacology of selective COX-2 inhibitors. Int. J. Immunopathol. Pharmacol. (2003) 16(Suppl.2):49-58.
   PubMed Web of Science ®Google Scholar
• ESSER R, BERRY C, DU Z et al.: Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclo-oxygenase-2. Br. J. Pharmacol. (2005) 144(4):538-550.
   PubMed Web of Science ®Google Scholar
• RORDORF C, SCOTT G, MILOSAVLJEV S, BLOOD P, BRANSON J, GREIG G: Steady state pharmacokinetics, pharmacodynamics, safety and tolerability of COX189 in healthy subjects. Ann. Rheum. Dis. (2002) 61(Suppl.1):420. Abstr. AB0284.
   Google Scholar
• ATHERTON C, JONES J, McKAIG B et al.: Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclo-oxygenase-2 selective inhibitor: an integrated study. Clin. Gastroenterol. Hepatol. (2004) 2(2):113-120.
   PubMed Web of Science ®Google Scholar
• LOZANO-CUENCA J, CASTANEDA-HERNANDEZ G, GRANADOS-SOTO V: Peripheral and spinal mechanisms of antinociceptive action of lumiracoxib. Eur. J. Pharmacol. (2005) 513(1-2):81-91.
   PubMedGoogle Scholar
• KALBAG J, YEH CM, MILOSAVLJEV S, LASSETER K, OBERSTEIN S, RORDORF C: No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor. Pharmacol. Res. (2004) 50(2):181-186.
   PubMed Web of Science ®Google Scholar
• MANGOLD JB, GU H, RODRIGUEZ LC, BONNER J, DICKSON J, RORDORF C: Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab. Dispos. (2004) 32(5):566-571.
   PubMed Web of Science ®Google Scholar
• SCOTT G, RORDORF C, REYNOLDS C et al.: Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin. Pharmacokinet. (2004) 43(7):467-478.
   PubMed Web of Science ®Google Scholar
• SCOTT G, RORDORF C, MILOSAVLJEV S, FERBER G: Pharmacokinetics and pharmacodynamics of COX 189 in patients with knee or hip primary osteoarthritis. Ann. Rheum. Dis. (2002) 61(Suppl.1):128. Abstr. THU0233.
   PubMedGoogle Scholar
• BONNER J, BRANSON J, MILOSAVLJEV S, RORDORF C, SCOTT G: Co-administration of lumiracoxib and warfarin does not alter the pharmacokinetic profile of R- or S- warfarin. Ann. Rheum. Dis. (2003) 62(Suppl.1):264. Abstr. FRI0225.
   PubMedGoogle Scholar
• SCOTT G, YIH L, YEH CM, MILOSAVLJEV S, LAURENT A, RORDORF C: Lumiracoxib: pharmacokinetic and pharmacodynamic profile when co-administered with fluconazole in healthy subjects. J. Clin. Pharmacol. (2004) 44(2):193-199.
   PubMedGoogle Scholar
• SCOTT G, VILUAN REYNOLDS C, MILOSAVLJEV S, LANGHOLFF W, SHENOUDA M, RORDORF C: Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. Clin. Pharmacokinet. (2004) 43(5):341-348.
   PubMed Web of Science ®Google Scholar
• HARTMANN SN, RORDORF CM, MILOSAVJLEV S et al.: Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. Ann. Pharmacother. (2004) 38(10):1582-1587.
   PubMed Web of Science ®Google Scholar
• KALBAG J, ELDER C, SCOTT G et al.: Concomitant administration of lumiracoxib and a triphasic oral contraceptive does not affect contraceptive activity or pharmacokinetic profile. J. Clin. Pharmacol. (2004) 44(6):646-654
   PubMed Web of Science ®Google Scholar
• JERMANY J, BRANSON J, SCHMOUDER R, GUILLAUME M, RORDORF C: Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects. J. Clin. Pharmacol. (2005) 45(10):1172-1178.
   PubMed Web of Science ®Google Scholar
• BERENBAUM F, GRIFFKA J, BROWN JP et al.: Efficacy of lumiracoxib in osteoarthritis: a review of nine studies. J. Int. Med. Res. (2005) 33(1):21-42.
   PubMed Web of Science ®Google Scholar
• WITTENBERG RH, SCHELL E, KREHAN G et al.: First-dose analgesic effect of the cyclo-oxygensase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo- controlled comparison with celecoxib [NCT00267215]. Arthritis Res. Ther. (2006) 8(2):R35.
   PubMedGoogle Scholar
• SCHNITZER TJ, BEIER J, GEUSENS P et al.: Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2004) 51(4):549-557.
   PubMed Web of Science ®Google Scholar
• TANNENBAUM H, BERENBAUM F, REGINSTER JY et al.: Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double-blind study versus placebo and celecoxib. Ann. Rheum. Dis. (2004) 63(11):1419-1426.
   PubMed Web of Science ®Google Scholar
• FLEISCHMANN R, SHELDON E, MALDANO-COCCO J, DUTTA D, YU S, SLOAN VS: Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib. Clin. Rheumatol. (2006) 25(1):42-53.
   PubMedGoogle Scholar
• GRIFKA JK, ZACHER J, BROWN JP et al.: Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand. Clin. Exp. Rheumatol. (2005) 22(5):589-596.
   Google Scholar
• SHELDON E, BEAULIEU A, PASTER Z, DUTTA D, YU S, SLOAN VS: Efficacy and tolerability of lumiracoxib the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo. Clin. Ther. (2005) 27(1):64-77.
   PubMedGoogle Scholar
• LEHMANN R, BRZOSKO M, KOPSA P et al.: Efficacy and tolerability of lumiracoxib once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib. Curr. Med. Res. Opin. (2005) 21(4):517-526.
   PubMed Web of Science ®Google Scholar
• TUBACH F, RAVAUD P, BARON G, FALISSARD B, LOGEART I, BELLAMY N et al.: Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann. Rheum. Dis. (2004) 64(1):29-33.
   PubMedGoogle Scholar
• TUBACH F, RAVAUD P, BARON G et al.: Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann. Rheum. Dis. (2004) 64(1):34-37.
   PubMedGoogle Scholar
• DOUGADOS M, MOORE A, YU S, GITTON X: Evaluation of patient acceptable symptom state (PASS) in a pooled analysis of two multicentre, randomized, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis. Arthritis Res. Ther. (2007) 9(1):R11.
   PubMed Web of Science ®Google Scholar
• ZELENAKAS K, FRICKE JR Jr, JAYAWARDENE J, KELLSTEIN D: Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental pain. Int. J. Clin. Pract. (2004) 58(3):251-256.
   PubMedGoogle Scholar
• KELLSTEIN D, OTT D, JAYAWARDENE J, FRICKE J: Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain. Int. J. Clin. Pract. (2004) 58(3):244-250.
   PubMed Web of Science ®Google Scholar
• CHAN VWS, CLARK AJ, DAVIS JC, WOLF RS, KELLSTEIN D, JAYAWARDENE S: The post-operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplasty. Acta Anaesthesiol. Scand. (2005) 49(10):1491-1495.
   PubMedGoogle Scholar
• BITNER M, KATTERNHORN J, HATFIELD C, GOA J, KELLSTEIN D: Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea. Int. J. Clin. Pract. (2004) 58(4):340-345.
   PubMedGoogle Scholar
• PACKMAN E, PACKMAN B, THURSTON H, TSENG L: Lumiracoxib is effective in the treatment of episodic tension-type headache. Headache (2005) 45(9):1163-1170.
   PubMedGoogle Scholar
• HAWKEY CJ, GITTON X, HOEXTER G, RICHARD D, WEINSTEIN WM: Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis. Clin. Gastroenterol. Hepatol. (2006) 4(1):57-66.
   PubMedGoogle Scholar
• HIRSCHBERG R, DELLA CASA ALBERIGHI O, HOEXTER G: Effect of lumiracoxib on blood pressure and fluid retention: a pooled analysis. Rheumatology (2004) 43(Suppl.2):ii66-ii67 (Abstr. 123).
   Google Scholar
• RORDORF C, KELLETT N, MAIR S et al.: Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen: a pilot endoscopic study in healthy male subjects. Aliment. Pharmacol. Ther. (2003) 18(5):533-541.
   PubMed Web of Science ®Google Scholar
• HAWKEY C, SVOBODA P, FIEDOROWICZ-FABRYCY IF et al.: Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis. J. Rheumatol. (2004) 31(9):1804-1810.
   PubMedGoogle Scholar
• KIVITZ AJ, NAYIAGER S, SCHIMANSKY T, GIMONA A, THURSTON AJ, HAWKEY C: Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment. Pharmacol. Ther. (2004) 19(11):1189-1198.
   PubMed Web of Science ®Google Scholar
• SCHNITZER TJ, BURMESTER GR, MYSLER E et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications : randomised controlled trial. Lancet (2004) 364(9435):665-674.
   PubMed Web of Science ®Google Scholar
• FARKOUH ME, KIRSHNER H, HARRINGTON RA et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet (2004) 364(9435):675-684.
   PubMed Web of Science ®Google Scholar
• MATCHABA P, GITTON X, KRAMMER G, EHRSAM E, SLOAN VS, OLSON M et al.: Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials ≥ 1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Clin. Ther. (2005) 27(8):1196-1214.
   PubMed Web of Science ®Google Scholar
• BEEJAY U, WOLFE MM: Cyclooxygenase 2 selective inhibitors: panacea or flash in the pan? Gastroenterology (1999) 117(4):1002-1005.
   PubMedGoogle Scholar
• TOPOL EJ, FALK GW: A coxib a day won’t keep the doctor away. Lancet (2004) 364(9435):638-639.
   PubMed Web of Science ®Google Scholar
• GROSSER T, FRIES S, FITZGERALD GA: Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. (2006) 116(1):4-15.
   PubMed Web of Science ®Google Scholar
• ROSTOM A, GOLDKIND L, LAINE L: Nonsteroidal anti-inflammatory drugs and hepatic toxicity: A systematic review of randomized controlled trials in arthritis patients. Clin. Gastroenterol. Hepatol. (2005) 3( ):489-498.
   PubMed Web of Science ®Google Scholar